Just (can’t) do it?

The discussion dives into Nike's dramatic stock decline and the fallout from its direct-to-consumer strategy, impacting longstanding retailer relationships. There's an exploration of how the sneaker boom might be peaking, with niche brands like On and Hoka seizing the opportunity. Shifting gears, the podcast reveals India's alarming drug quality issues, spotlighting regulatory challenges and chronic inspector shortages. It highlights the systemic failures behind contaminated medicines, emphasizing the urgent need for reform in oversight practices.